Indeed, the Guiding Evidence-based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) trial showed that a therapeutic strategy guided by N-terminal pro-B-type NP (NT-proBNP) does not lead to better outcomes than a usual care strategy [8]. This evidence concerns the gene NPPB and heart failure.